Cargando…
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
Autores principales: | Ruhnke, Leo, Röllig, Christoph, Herold, Sylvia, Sauer, Tim, Brandts, Christian H., Steffen, Björn, Schäfer-Eckart, Kerstin, Krause, Stefan W., Hänel, Mathias, Reichle, Albrecht, Scholl, Sebastian, Neubauer, Andreas, Mikesch, Jan-Henrik, Schetelig, Johannes, Stölzel, Friedrich, Kramer, Michael, Haake, Annett, Frimmel, Julia, Krämer, Alwin, Schlenk, Richard, Platzbecker, Uwe, Serve, Hubert, Baldus, Claudia D., Müller-Tidow, Carsten, Aust, Daniela, Bornhäuser, Martin, Ehninger, Gerhard, Thiede, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483343/ https://www.ncbi.nlm.nih.gov/pubmed/36779591 http://dx.doi.org/10.3324/haematol.2022.281636 |
Ejemplares similares
-
Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study
por: Krug, Utz, et al.
Publicado: (2012) -
Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
por: Stasik, Sebastian, et al.
Publicado: (2022) -
Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD
por: Stasik, Sebastian, et al.
Publicado: (2022) -
Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms
por: Ruhnke, Leo, et al.
Publicado: (2021) -
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
por: Hanoun, Maher, et al.
Publicado: (2022)